Viewing Study NCT05755360


Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2026-03-08 @ 3:19 AM
Study NCT ID: NCT05755360
Status: COMPLETED
Last Update Posted: 2025-10-02
First Post: 2023-02-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
Sponsor: Novo Nordisk A/S
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diabetes Mellitus, Type 2 View
Keywords: